Interim phase III trial data shows rVSV-ZEBOV vaccine 100% effective against ebola- Merck Inc/NewLink Genetics
Merck said that its investigational Ebola vaccine candidate, rVSV-ZEBOV, from Merck Inc/NewLink Genetics, was found to have 100 percent efficacy in an analysis of interim data from a Phase III ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line in The Lancet. The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 - 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination. According to Nature, the authors of the paper put its true effectiveness at between 75% and 100%.
To date, more than 4,000 participants have received the vaccine in this innovative trial, called "Ebola �a suffit" or "Ebola, that's enough." The trial was conducted by a team that included researchers from the World Health Organization (WHO), the Norwegian Institute of Public Health, the Health Ministry of Guinea and M�decins sans Fronti�res, among others.
Comment: �We believe the world is on the verge of an efficacious Ebola vaccine," Marie-Paule Kieny, the World Health Organization's assistant director-general for health systems and innovation, said during a press conference in Geneva, Switzerland.
See: "Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial" Ana Maria Henao-Restrepo et al. The Lancet, July 31, 2015 http://dx.doi.org/10.1016/S0140-6736(15)61117-5
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins